



## **Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference**

May 9, 2018

BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executive Officer of Rhythm, will present a corporate update at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 5:00 p.m. PT (8:00 p.m. ET) in Las Vegas, NV.

A live audio webcast of the presentation will be available under "Events & Presentations" in the Investors & Media section of the Company's website at [www.rhythmtx.com](http://www.rhythmtx.com). A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.

### **About Rhythm**

Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the Company's first-in-class melanocortin-4 receptor (MC4R) agonist, in Phase 3 studies in patients with pro-opiomelanocortin (POMC) deficiency obesity (which includes deficiencies in both the POMC and PCSK1 genes) and leptin receptor (LEPR) deficiency obesity. Rhythm also supports The Genetic Obesity Project ([www.GeneticObesity.com](http://www.GeneticObesity.com)), which is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. The company is based in Boston, MA.

### **Investor Contact:**

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

### **Media Contact:**

Adam Daley  
Berry & Company Public Relations  
212-253-8881  
[adaley@berrypr.com](mailto:adaley@berrypr.com)



Rhythm Pharmaceuticals, Inc.